McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin E. Noonan authored an article entitled, “Does the Myriad decision presage a golden age of patent-free personalized medicine?” that appears in the September 2013 online edition of DDNEWS. The U.S. Supreme Court’s Myriad decision has been almost universally hailed as being a great victory for patients, doctors, personalized medicine and research. Indeed, several genetic analysis companies announced plans to offer BRCA gene testing. The natural question to ask is: Are all of these “experts” correct? View the article